O'Dwyer, Michael
4 papers on CoChatORCID 0000-0002-6173-7140
Most cited papers
- Verified
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2021) · The Lancet Oncology
Multiple Myeloma Research and TreatmentsBone health and treatments
Cited by 370
- Verified
Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma
Vincenz, L., Jäger, R., O'Dwyer, M., & Samali, A. (2013) · Molecular Cancer Therapeutics
Endoplasmic Reticulum Stress and DiseaseMultiple Myeloma Research and Treatments
Cited by 175
- Verified
Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)
Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2018) · Blood
Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research
Cited by 50
- Verified
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., et al. (2022) · The Lancet Haematology
Multiple Myeloma Research and TreatmentsBone health and treatments
Cited by 48
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free